Literature DB >> 8691133

Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

H Groux1, M Bigler, J E de Vries, M G Roncarolo.   

Abstract

Human CD4+ T cells, activated by allogeneic monocytes in a primary mixed lymphocyte reaction in the presence of exogenous interleukin (IL) 10, specifically failed to proliferate after restimulation with the same alloantigens. A comparable state of T cell unresponsiveness could be induced by activation of CD4+ T cells by cross-linked anti-CD3 monoclonal antibodies (mAbs) in the presence of exogenous IL-10. The anergic T cells failed to produce IL-2, IL-5, IL-10, interferon gamma, tumor necrosis factor alpha, and granulocyte/macrophage colony-stimulating factor. The IL-10-induced anergic state was long-lasting. T cell anergy could not be reversed after restimulation of the cells with anti-CD3 and anti-CD28 mAbs, although CD3 and CD28 expression was normal. In addition, restimulation of anergized T cells with anti-CD3 mAbs induced normal Ca2+ fluxes and resulted in increased CD3, CD28, and class II major histocompatibility complex expression, indicating that calcineurin-mediated signaling occurs in these anergic cells. However, the expression of the IL-2 receptor alpha chain was not upregulated, which may account for the failure of exogenous IL-2 to reverse the anergic state. Interestingly, anergic T cells and their nonanergic counterparts showed comparable levels of proliferation and cytokine production after activation with phorbol myristate acetate and Ca2+ ionophore, indicating that a direct activation of a protein kinase C-dependent pathway can overcome the tolerizing effect of IL-10. Taken together, these data demonstrate that IL-10 induces T cell anergy and therefore may play an important role in the induction and maintenance of antigen-specific T cell tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691133      PMCID: PMC2192687          DOI: 10.1084/jem.184.1.19

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  Maintenance of in vivo tolerance by persistence of antigen.

Authors:  F Ramsdell; B J Fowlkes
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 2.  The role of cell division in the induction of clonal anergy.

Authors:  M K Jenkins
Journal:  Immunol Today       Date:  1992-02

3.  Transactivation by AP-1 is a molecular target of T cell clonal anergy.

Authors:  S M Kang; B Beverly; A C Tran; K Brorson; R H Schwartz; M J Lenardo
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

4.  IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function.

Authors:  L Ding; E M Shevach
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

5.  Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation.

Authors:  D R DeSilva; K B Urdahl; M K Jenkins
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

6.  IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells.

Authors:  H Yssel; R De Waal Malefyt; M G Roncarolo; J S Abrams; R Lahesmaa; H Spits; J E de Vries
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

7.  Infection breaks T-cell tolerance.

Authors:  M Röcken; J F Urban; E M Shevach
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

8.  Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures.

Authors:  M T Bejarano; R de Waal Malefyt; J S Abrams; M Bigler; R Bacchetta; J E de Vries; M G Roncarolo
Journal:  Int Immunol       Date:  1992-12       Impact factor: 4.823

9.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

Authors:  P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper
Journal:  Science       Date:  1992-08-07       Impact factor: 47.728

10.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  185 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?

Authors:  K Honey; S P Cobbold; H Waldmann
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 4.  Controlling mature CD4+ T cell responses.

Authors:  M E Ozaki; S R Webb
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 5.  Control of immune pathology by IL-10-secreting regulatory T cells.

Authors:  S Fowler; F Powrie
Journal:  Springer Semin Immunopathol       Date:  1999

Review 6.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 7.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

8.  Regulatory function of in vivo anergized CD4(+) T cells.

Authors:  K Jooss; B Gjata; O Danos; H von Boehmer; A Sarukhan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

9.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

10.  Allergen-specific CD8(+) T cells and atopic disease.

Authors:  Suranjith L Seneviratne; Louise Jones; Abigail S King; Antony Black; Sheila Powell; Andrew J McMichael; Graham S Ogg
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.